Verovaccines

Germany
Herrnhut, Saxony, Germany, 06120

Company profile

Verovaccines company profile

VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases (proof-of-concept). VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.

Business identity

Phone number
+49 345 5526309
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2017-01-01, Year

Headquarters

Postal code
06120
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Last funding
Series B / 2021-10-14
Last equity funding
Series B
Investors
3
Lead investors
2
Founders
2
Articles
4

Founders and investors

Founders

Hanjo HennemannSven-erik behrens

Lead investors

German Federal Ministry of Education and ResearchHTGF (High-Tech Gruenderfonds)

Investors

Business Angels Switzerland (BAS)German Federal Ministry of Education and ResearchHTGF (High-Tech Gruenderfonds)